Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases

Boehringer Ingelheim

Status: Completed

Conditions: Arthritis, Rheumatoid

Treatments: Drug: Meloxicam

Study type: Observational

Funder types: Industry

Identifiers

NCT02184065

107.272

Details and patient eligibility

About

Observational study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases

Enrollment: 22,639 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age of 12 or older and rheumatologic disease

Exclusion criteria

• Hypersensitivity to meloxicam
• Hypersensitivity to other Non-steroidal anti-inflammatory drugs (NSAIDS)
• History of asthma, angioedema or urticaria secondary to NSAIDS
• Pregnancy or lactation
• Recent or current history of peptic ulcer disease, severe renal failure and severe hepatic failure

Trial design

22,639 participants in 1 patient group

Meloxicam

Treatment:

Drug: Meloxicam